Clinical Trial: Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)

U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT07600983) titled 'Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)' on May 15.

Brief Summary: This clinical trial consists of Phase I and Phase II. The objective is to evaluate the safety and immunogenicity of the 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) in individuals aged 2 months (minimum 6 weeks) and older.

Study Start Date: May 24

Study Type: INTERVENTIONAL

Condition: Streptococcus Pneumoniae Infection

Intervention: BIOLOGICAL: 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) (referred to as PCV24) (dose M)

1 dose ( 0....